This medical condition has either been superseded or has become inactive
| Specific Conditions |
|
| Level of Evidence | Evidence of probable benefit – more research needed (Category 2a) |
|
The need for intravenous immunoglobulin (IVIg) in paediatric HIV has been substantially reduced with the advent of highly active antiretroviral therapy (HAART). A trial of therapy may, however, be considered in children with significant recurrent bacterial infections despite HAART. Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. |
|
| Bibliography |
|---|
| Orange, JS, Hossny, EM, Weiler, CR, et al 2006, ‘Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology’, Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. S525–53. |